Becker's Healthcare December 26, 2024
Jakob Emerson

Insurers and self-funded employers are making significant changes to their GLP-1 drug coverage policies in 2025, reflecting the financial and operational challenges posed by the high-cost medications.

Among U.S. adults, 80% say insurers should cover weight loss drugs for adults diagnosed as overweight or obese, according to an August 2023 survey from KFF. Half of respondents also said insurance should cover the drugs even if it would increase premium costs. Over 42% of U.S. adults (57.4 million) under 65 with private insurance could be eligible for GLP-1 drugs, based on current FDA indications, according to a Sept. analysis from KFF.

According to a Mercer survey of more than 2,000 employers in 2024, 44% with 500 or more employees offer...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Pharma / Biotech, Survey / Study, Trends
Gene Therapy for Cardiomyopathies Presents Promising Alternative to Current Treatment
STAT+: 3 trends to watch in biotech in 2025
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs

Share This Article